Last updated: October 31, 2026
Executive summary: ABECMA (idecabtagene vicleucel) generated rapid commercial growth after its 2021 launch, with Bristol Myers Squibb reporting worldwide sales of $164 million in 2021, $356 million in 2022 and $457 million in 2023. The commercial outlook changed in 2024 after FDA approval moved ABECMA into earlier-line treatment for multiple myeloma, while intensified competition from CARVYKTI and BCMA-directed bispecific antibodies increased pricing, sequencing and market-share pressure. ABECMA has a durable regulatory position, but its financial trajectory depends on manufacturing throughput, physician preference, comparative outcomes and access in the second-line and later-line settings.
ABECMA Market Dynamics, Revenue Growth, Patent Protection and Competitive Outlook
Publicly reported financial data are available through fiscal year 2023, with major FDA developments through April 2024.
What is ABECMA and how does its FDA label affect market demand?
ABECMA is an autologous CAR T-cell therapy containing idecabtagene vicleucel, a genetically modified T-cell product directed against B-cell maturation antigen, or BCMA. Bristol Myers Squibb and 2seventy bio developed the product through their collaboration.
The FDA first approved ABECMA on March 26, 2021, for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.[1]
On April 5, 2024, the FDA expanded ABECMA's indication to adults with relapsed or refractory multiple myeloma after at least two prior lines of therapy, including lenalidomide, where the disease is refractory to lenalidomide.[2] This earlier-line approval materially expanded the eligible population and increased the addressable market.
ABECMA FDA milestones
| Date |
Regulatory event |
Commercial effect |
| March 26, 2021 |
Initial FDA approval after four or more prior therapies |
Established ABECMA in heavily pretreated myeloma |
| 2021 |
First commercial sales |
Initial uptake constrained by referral, manufacturing and treatment-center capacity |
| April 5, 2024 |
Approval after two or more prior therapies in lenalidomide-refractory disease |
Expanded the market into earlier-line treatment |
| Ongoing |
REMS and boxed warnings for CRS, neurologic toxicities, prolonged cytopenias and secondary malignancies |
Maintains treatment-site and monitoring requirements |
The earlier-line label is strategically important because patients treated after two prior lines generally have better performance status and larger treatment pools than patients after four or more lines. That benefit is offset by stronger competition from CARVYKTI and non-cellular BCMA therapies.
How much revenue does ABECMA generate?
Bristol Myers Squibb reported the following worldwide ABECMA revenue:
| Fiscal year |
Worldwide sales |
Year-over-year change |
| 2021 |
$164 million |
Initial launch year |
| 2022 |
$356 million |
Approximately 117% |
| 2023 |
$457 million |
Approximately 28% |
| 2024 |
Not included in this analysis |
Public reporting after the stated data period |
Sources: Bristol Myers Squibb annual reports and 2023 Form 10-K.[3]
The trajectory shows strong launch expansion through 2023. Growth came from broader treatment-center activation, increased physician familiarity, improved manufacturing execution and use in heavily pretreated patients. The 2024 label expansion creates a larger revenue opportunity, but it does not guarantee equivalent sales growth because earlier-line myeloma has a more competitive treatment environment.
ABECMA economics also involve 2seventy bio. Under the companies' collaboration, 2seventy participates in the U.S. commercial economics, while Bristol Myers Squibb has major responsibility for global commercialization outside the United States. The arrangement gives 2seventy a concentrated economic exposure to ABECMA and makes product performance central to its corporate finances.[4]
What drives ABECMA revenue growth?
The main revenue drivers are:
- Earlier-line eligibility after the 2024 label expansion.
- Greater availability of qualified CAR T treatment centers.
- Improved manufacturing turnaround times.
- Increased use in patients previously exposed to lenalidomide.
- Reimbursement acceptance for high-cost inpatient or outpatient administration.
- Physician preference for a one-time cellular therapy over repeated infusions.
The principal constraints are manufacturing slots, patient referral delays, lymphodepletion and inpatient monitoring requirements, treatment-related toxicity, and competition for patients who are eligible for more than one BCMA-directed therapy.
How does ABECMA compare with CARVYKTI?
CARVYKTI, or ciltacabtagene autoleucel, is ABECMA's closest commercial competitor. Janssen Biotech and Legend Biotech developed CARVYKTI, which was approved by the FDA in February 2022 for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy. Its label later expanded into earlier treatment settings.
| Factor |
ABECMA |
CARVYKTI |
| Active product |
Idecabtagene vicleucel |
Ciltacabtagene autoleucel |
| Target |
BCMA |
BCMA |
| Initial FDA approval |
March 2021 |
February 2022 |
| Initial treatment setting |
Four or more prior lines |
Four or more prior lines |
| Earlier-line expansion |
Two or more prior lines in lenalidomide-refractory disease |
Expanded to earlier-line settings in 2024 |
| Commercial sponsors |
Bristol Myers Squibb and 2seventy bio |
Janssen and Legend Biotech |
| Main competitive issue |
Established treatment-center base and commercial experience |
Strong efficacy profile and demand growth |
| Manufacturing issue |
Capacity and turnaround remain relevant |
Supply constraints have also affected uptake |
The pivotal KarMMa-3 trial reported a median progression-free survival of 13.3 months for ABECMA compared with 4.4 months for standard regimens in patients with two to four prior lines of therapy.[5] In CARTITUDE-4, CARVYKTI produced a median progression-free survival of 11.2 months compared with 4.2 months for standard regimens in a related earlier-line population.[6]
These results are not head-to-head comparisons. Cross-trial efficacy comparisons should not be treated as direct evidence of superiority. Commercially, CARVYKTI has benefited from strong response data, while ABECMA benefits from being first to market and from established U.S. treatment infrastructure.
What other therapies compete with ABECMA?
ABECMA competes across several treatment classes:
BCMA-directed bispecific antibodies
Tecvayli, or teclistamab, from Johnson & Johnson, and Elrexfio, or elranatamab, from Pfizer, are off-the-shelf BCMA-directed bispecific antibodies. Talvey, or talquetamab, from Johnson & Johnson, targets GPRC5D.
Bispecific antibodies have a commercial advantage because they do not require leukapheresis, individualized manufacturing or a product-specific production slot. They can be administered repeatedly and may be easier to deploy in community settings. Their disadvantages include recurring treatment costs, ongoing administration and risks such as cytokine release syndrome, infections and hypogammaglobulinemia.
Conventional myeloma regimens
ABECMA also competes with combinations involving proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, selinexor and other agents. In earlier-line disease, oncologists may preserve CAR T therapy for later treatment or choose a bispecific antibody based on disease tempo, patient frailty and treatment-center access.
Transplant and clinical trials
Autologous stem-cell transplantation remains relevant for selected patients. Clinical trials involving next-generation CAR T products, dual-target CAR T therapies, allogeneic cell therapies and bispecific combinations may affect ABECMA's long-term position.
When does ABECMA lose exclusivity?
ABECMA does not have a conventional Orange Book patent-and-exclusivity profile because it is a biologic product rather than a small-molecule drug. FDA's Orange Book generally lists approved drug products and relevant patents for small-molecule applications. Biologic reference products are tracked through the Purple Book framework.[7]
ABECMA received 12 years of U.S. reference-product exclusivity from its first licensure date, subject to statutory rules and any applicable pediatric extension. Based on the March 26, 2021 approval date, the principal biologic exclusivity period extends to approximately March 26, 2033.[1]
That date is not the same as the expiration of every patent protecting ABECMA. The product may be covered by patents relating to:
- The anti-BCMA binding domain and CAR architecture.
- Nucleic-acid and vector design.
- T-cell activation and manufacturing methods.
- Cell expansion, transduction and formulation.
- Treatment of multiple myeloma with ide-cel.
- Quality control and release testing.
Patent expiration depends on the specific patent family, priority claims, patent-term adjustment, terminal disclaimers and any patent-term extension. FDA approval materials do not provide a consolidated public patent-expiration schedule for ABECMA.
Are there Paragraph IV challenges to ABECMA?
A conventional Paragraph IV certification is generally not the expected pathway for ABECMA because Paragraph IV litigation is associated with Orange Book-listed patents for abbreviated new drug applications. A future biosimilar or interchangeable product would proceed under the Public Health Service Act's section 351(k) pathway and the Biologics Price Competition and Innovation Act framework.[8]
No biosimilar competition is an immediate commercial substitute for ABECMA. Autologous CAR T products require patient-specific collection, manufacturing and release. A follow-on product would need to address biological comparability, manufacturing consistency, clinical development, treatment-center logistics and regulatory interchangeability considerations.
What is the patent strength of the ABECMA estate?
ABECMA's patent position is technically layered but commercially complex. The strongest barriers are likely to arise from the combination of product-specific manufacturing, regulatory exclusivity, treatment-center qualification and know-how rather than from a single composition-of-matter patent.
| Protection category |
Relevance to ABECMA |
Competitive significance |
| CAR construct |
Defines targeting and signaling architecture |
Can restrict closely related engineered products |
| BCMA binding sequence |
May protect product-specific antigen recognition |
Potentially important against similar CAR designs |
| Viral vector and transduction |
Supports genetic modification of T cells |
Adds manufacturing patent density |
| Cell-processing methods |
Covers expansion, activation and release steps |
Creates process barriers for follow-on products |
| Formulation and cryopreservation |
Supports stability and distribution |
Relevant to commercial logistics |
| Method of use |
Covers treatment of myeloma with ide-cel |
May affect labeled or induced use |
| Regulatory exclusivity |
Twelve-year U.S. biologic reference exclusivity |
Delays biosimilar approval based on the reference product |
The practical strength of the estate is therefore greater than a simple patent-count analysis suggests. A competitor could potentially design around an individual patent but still face the cumulative burden of developing an alternative CAR construct, manufacturing process and clinical package.
What litigation and settlement risks affect ABECMA?
Public company filings through fiscal year 2023 did not identify a major ABECMA-specific Paragraph IV case comparable to the litigation typically seen for small-molecule products. The principal legal risks are more likely to involve:
- CAR architecture and antigen-binding patents.
- Manufacturing-process disputes.
- Employee or inventor ownership claims.
- License interpretation between the historical Celgene, Juno, bluebird bio and 2seventy-related rights.
- Patent challenges involving competing CAR T developers.
- Contractual disputes over global commercialization and profit-sharing.
No major publicly disclosed ABECMA settlement agreement materially changes the product's market-entry timeline in the stated data period.
How important is manufacturing to ABECMA's commercial outlook?
Manufacturing is a central commercial variable. ABECMA is made from the patient's own T cells, which requires leukapheresis, shipment to a manufacturing site, genetic modification, expansion, quality testing, cryopreservation and return to the treatment center.
The manufacturing chain creates several revenue risks:
- Patient deterioration before infusion.
- Production failure or out-of-specification product.
- Delayed turnaround times.
- Limited slots at qualified manufacturing facilities.
- Competition for hospital capacity.
- Higher costs associated with inpatient monitoring and toxicity management.
An off-the-shelf bispecific antibody avoids most of these steps. ABECMA's commercial advantage depends on producing a durable response that justifies the operational burden of a one-time therapy.
What are the likely ABECMA launch and market-share scenarios?
Upside scenario
The 2024 earlier-line label expansion increases patient flow, manufacturing capacity improves, and physicians select ABECMA for lenalidomide-refractory patients before repeated bispecific exposure. Under this scenario, revenue growth resumes after the initial launch curve and ABECMA remains a major BCMA CAR T product.
Base scenario
ABECMA maintains a substantial position in U.S. multiple myeloma, but market share is divided among CARVYKTI, bispecific antibodies and conventional regimens. Revenue grows more slowly than the 2021 to 2023 trajectory because the earlier-line segment is contested.
Downside scenario
CARVYKTI captures a disproportionate share of earlier-line CAR T use, while bispecific antibodies absorb patients who cannot wait for manufacturing. ABECMA revenue then depends heavily on later-line treatment, international expansion and differentiated safety or operational performance.
How does ABECMA compare with other Bristol Myers Squibb assets?
ABECMA is strategically smaller than Bristol Myers Squibb's leading checkpoint inhibitor and cardiovascular franchises, but it is important as a cell-therapy platform and as a high-value product in hematologic oncology. The asset's revenue concentration creates greater volatility than a chronic oral therapy because sales depend on treatment-center activation, patient referrals and one-time administration.
For 2seventy bio, the exposure is much more concentrated. ABECMA performance affects collaboration revenue, cash generation and the company's ability to fund additional cell-therapy programs.[4]
Key takeaways
- ABECMA sales increased from $164 million in 2021 to $457 million in 2023.
- The April 2024 FDA approval expanded ABECMA into patients after two or more prior therapies who are refractory to lenalidomide.
- CARVYKTI is the closest competitor and has strong efficacy-driven commercial momentum.
- BCMA and GPRC5D bispecific antibodies create an off-the-shelf alternative to autologous CAR T therapy.
- ABECMA's U.S. biologic exclusivity period runs approximately through March 2033, while individual patent terms may differ.
- Orange Book and Paragraph IV analysis is less applicable because ABECMA is a biologic cell therapy.
- Manufacturing capacity, turnaround time and qualified treatment-center access are as important as clinical efficacy.
- The 2024 label expansion increases the market opportunity but also exposes ABECMA to more direct competition.
FAQs
Is ABECMA a biosimilar?
No. ABECMA is an original biologic CAR T-cell therapy. A future competing product would need to pursue the 351(k) biosimilar pathway or another applicable biologic approval route.
Is ABECMA covered by Medicare?
Coverage depends on the treatment setting, patient eligibility, site-of-care requirements and applicable Medicare payment rules. Medicare coverage does not eliminate hospital capacity, authorization or referral constraints.
Can ABECMA be used after CARVYKTI?
Treatment sequencing is a clinical decision. Prior CAR T exposure, antigen expression, disease status, toxicity history and available alternatives affect whether another cellular therapy is appropriate.
Does ABECMA have an interchangeability designation?
No. ABECMA is not designated as an interchangeable biosimilar because it is the reference CAR T product rather than a biosimilar.
What is the main commercial risk to ABECMA?
The largest commercial risk is loss of earlier-line share to CARVYKTI and off-the-shelf bispecific antibodies, especially if those products offer faster access, stronger physician preference or more favorable treatment-center economics.
References
-
U.S. Food and Drug Administration. (2021). ABECMA prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024, April 5). FDA approves idecabtagene vicleucel for earlier-line treatment of multiple myeloma. FDA.
-
Bristol Myers Squibb. (2024). 2023 annual report and Form 10-K. Bristol Myers Squibb.
-
2seventy bio, Inc. (2024). 2023 annual report and Form 10-K. 2seventy bio.
-
Munshi, N. C., Anderson, L. D., Jr., Shah, N., et al. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384(8), 705-716.
-
San-Miguel, J., Dhakal, B., Yong, K., et al. (2023). Ciltacabtagene autoleucel versus standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389, 335-347.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, ยงยง 7001-7003.
